Lindbrook Capital’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Lindbrook Capital’s Portfolio IMPL Stock Details IMPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,056	Closed	-$1.31K	–	2849
2023 Q3	$1.31K	Hold	3,056	–	–	﹤0.01%	2272
2023 Q2	$3.88K	Hold	3,056	–	–	﹤0.01%	1907
2023 Q1	$4.28K	Hold	3,056	–	–	﹤0.01%	1913
2022 Q4	$11.5K	Hold	3,056	–	–	﹤0.01%	1374
2022 Q3	$15K	Hold	3,056	–	–	﹤0.01%	1150
2022 Q2	$28K	Hold	3,056	–	–	﹤0.01%	866
2022 Q1	$19K	Hold	3,056	–	–	﹤0.01%	1033
2021 Q4	$26K	Buy	3,056 +1,156	+61%	+$11.5K	﹤0.01%	936
2021 Q3	$23K	Buy	+1,900	New	+$27.6K	0.01%	699

Other funds holding IMPL

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Lindbrook Capital's IMPL Position: Q4 2023 in Review

Lindbrook Capital sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 3,056 shares — an estimated $1.31K sold.

Lindbrook Capital first reported a position in IMPL in Q3 2021 and held it in 9 quarters. The position peaked at $28K in Q2 2022. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

Lindbrook Capital reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Lindbrook Capital sold 3,056 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $1.31K.
Lindbrook Capital first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q3 2021 and held it in 9 quarters.
Lindbrook Capital's Impel Pharmaceuticals Inc. Common Stock position peaked at $28K in Q2 2022.
2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on Lindbrook Capital's 13F filing for Q4 2023, filed 1 Feb 2024.